Last reviewed · How we verify

Guangdong Longchuangji Pharmaceutical Co., Ltd. — Portfolio Competitive Intelligence Brief

Guangdong Longchuangji Pharmaceutical Co., Ltd. pipeline: 0 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Vaginal Lactobacillus Dual Probiotic Capsules Vaginal Lactobacillus Dual Probiotic Capsules phase 3 Probiotic Gynecology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. BioBalance Corporation · 1 shared drug class
  2. Biocodex · 1 shared drug class
  3. CD Pharma India Pvt. Ltd. · 1 shared drug class
  4. CHU de Quebec-Universite Laval · 1 shared drug class
  5. Chuncheon Sacred Heart Hospital · 1 shared drug class
  6. Dow University of Health Sciences · 1 shared drug class
  7. Federico II University · 1 shared drug class
  8. Aga Khan University · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Guangdong Longchuangji Pharmaceutical Co., Ltd.:

Cite this brief

Drug Landscape (2026). Guangdong Longchuangji Pharmaceutical Co., Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/guangdong-longchuangji-pharmaceutical-co-ltd. Accessed 2026-05-17.

Related